3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Carcinoma, Renal Cell
4
Carcinoma, Hepatocellular
3
Melanoma
2
Endometrial Neoplasms
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Brain Neoplasms
1
Bone Neoplasms
1
Advanced Malignancies
1
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
1
Adenocarcinoma
1
Interventions
Carboplatin
11
atezolizumab
10
Etoposide
9
durvalumab
6
Topotecan
6
PM 01183
6
Specimen Handling
4
pembrolizumab
3
Magnetic Resonance Spectroscopy
3
Irinotecan
2
Injections
2
Drug Therapy
2
Cisplatin
2
Biopsy
2
AMG 757
2
tremelimumab
1
trastuzumab deruxtecan
1
toripalimab
1
olaparib
1
lenvatinib
1
fludarabine
1
enzalutamide
1
cabozantinib
1
berzosertib
1
avelumab
1
arginine decarboxylase
1
amrubicin
1
Vaccines
1
Taxes
1
Sodium Chloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
lenvatinib
×
30 days
×
Clear all
NCT04938817
2026-06-01
KEYNOTE-B98
Merck Sharp & Dohme LLC
Phase 1/2
Active not recruiting
110 enrolled